Lexaria Bioscience (LEXX) Stock
What Lexaria Bioscience's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -11.6x
- Revenue growth
- -68.5%
- Operating margin
- -3,973.2%
- Debt / equity
- 0.00x
What Lexaria Bioscience's price implies
Lexaria Bioscience's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Lexaria Bioscience's 10-K filings.
Lexaria Bioscience revenue and free cash flow
FY2016–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $722,738 | $255,397 | $226,208 | $464,278 | $705,923 |
| Net income | -$4M | -$7M | -$7M | -$6M | -$12M |
| Free cash flow | — | -$5M | -$6M | -$5M | -$10M |
| EPS (diluted) | -$0.95 | — | -$1.01 | -$0.47 | -$0.66 |
| Operating margin | -786.8% | -2,591.7% | -2,888.5% | -1,239.2% | -1,683.0% |
Where the revenue comes from
By products, fiscal 2025. By year
Superinvestors who own LEXX
From each investor's latest 13F filing (what a 13F shows).
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Jim Simons Renaissance Technologies | Added | $9,240 | 0.0% | Q2 2026 |
Lexaria Bioscience insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of LEXX in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from LEXX's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Lexaria Bioscience compares
Lexaria Bioscience's revenue growth is higher than 7% of Healthcare companies and 2% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 7% | 2% |
| Operating margin | 5% | 1% |
| ROE | 4% | 2% |
Questions about Lexaria Bioscience
Are Lexaria Bioscience insiders buying the stock?
No open-market insider purchases of LEXX in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Lexaria Bioscience?
1 of the superinvestors Investingly tracks hold LEXX in their latest 13F, including Jim Simons.
Companies like Lexaria Bioscience
Anixa Biosciences Inc (ANIX)$110MLENZ Therapeutics Inc (LENZ)$110MFoghorn Therapeutics Inc (FHTX)$110MCellectis SA (CLLS)$107MOnKure Therapeutics, Inc. (OKUR)$116MVoyager Therapeutics, Inc. (VYGR)$116MAnavex Life Sciences Corp (AVXL)$107MenGene Holdings Inc. Common Stock (ENGN)$117MImmunic Inc (IMUX)$106M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.